Anti-ACADM/MCAD antibody [3B7BH7]

6 product images

• 

  Western blot - Anti-ACADM/MCAD antibody [3B7BH7] (ab110296)

  All lanes: Western blot - Anti-ACADM/MCAD antibody [3B7BH7] (ab110296) at 0.125 µg/mL

  Lane 1: HepG2 cell lysates at 15 µg

  Lane 2: HeLa cell lysates at 15 µg

  Lane 3: H9C2 (rat cells) lysates at 15 µg

  Lane 4: MEF (mouse cells) lysates at 15 µg

  Predicted band size: 47 kDa

• 

  Flow Cytometry - Anti-ACADM/MCAD antibody [3B7BH7] (ab110296)

  HL-60 cells were stained with 1 µg/mL ab110296 (blue) or an equal amount of an isotype control antibody (red) and analyzed by flow cytometry.

• 

  Immunocytochemistry/ Immunofluorescence - Anti-ACADM/MCAD antibody [3B7BH7] (ab110296)

  Immunocytochemistry image of ab110296 stained Human HeLa cells. The cells were paraformaldehyde fixed (4%, 20 minutes) and Triton X-100 permeabilized (0.1%, 15 minutes). The cells were incubated with ab110296 (1 µg/ml) for 2 hours at room temperature or over night at 4°C. The secondary antibody was (green) Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1 hour. 10% Goat serum was used as the blocking agent for all blocking steps. DAPI was used to stain the cell nuclei (blue). Target protein locates mainly in mitochondria.

• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ACADM/MCAD antibody [3B7BH7] (ab110296)

  ACADM/MCAD immunohistochemistry in Human cerebellum visualized with ab110296 at 1/1000. MCAD immunoactivity is most intense in neuronal cell bodies, most notably in the large Purkinje cells. Note the distinctive subcellular localization of MCAD immunoreactivity in the Purkinje cell bodies.

• 

  Western blot - Anti-ACADM/MCAD antibody [3B7BH7] (ab110296)

  HL-60 cells were incubated at 37°C for 24h with vehicle control (0 μM) and different concentrations of fenofibrate (Fenofibrate, PPAR-alpha agonist ab120832). Increased expression of ACADM/MCAD in HL-60 cells correlates with an increase in fenofibrate concentration, as described in literature.
  

  Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10μg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab110296 at 1 μg/ml and Anti-GAPDH antibody [mAbcam 9484] - Loading Control ab9484 at 1 μg/ml overnight at 4°C. Antibody binding was detected using an anti-mouse antibody conjugated to HRP (Goat Anti-Mouse IgG H&L (HRP) preadsorbed ab97040) at 1/10000 dilution and visualised using ECL development solution.

  All lanes: Western blot - Anti-ACADM/MCAD antibody [3B7BH7] (ab110296)

  Developed using the ECL technique.

  Performed under reducing conditions.

  Predicted band size: 47 kDa

• 

  Image collected and cropped by CiteAb under a CC-BY license from the publication

  Western blot - Anti-ACADM/MCAD antibody [3B7BH7] (ab110296)

  ACADM/MCAD western blot using anti-ACADM/MCAD antibody [3B7BH7] ab110296. Publication image and figure legend from Gao, K., Zhang, J., et al., 2020, Chin Med, PubMed 32158496.

  
  

  ab110296 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab110296 please see the product overview.

  Effects of QSG on FAT/CD36-CPT1-FAO pathway in HF rats after AMI. The protein expressional levels of CD36, CPT1A, ACADL, ACADM, ACAA2 and SCP2 in the three groups were significantly decreased in the model group compared with the sham group. After treatment with QSG, cardiac CD36, CPT1A, ACADL, ACADM, ACAA2 and SCP2 levels were all significantly increased. n = 4 per group. Values are mean ± SE. Asterisks indicates significant differences. *P < 0.05, **P < 0.01